The immune system of tumor-bearing patients and experimental animals is adversely affected by the tumor, even early in the course of disease. A recent meeting* focused on the mechanisms involved in this phenomenon and their implications for cancer immunotherapy.
机构:
John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, EnglandJohn Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England